BCLX(L) blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.

Venkatachalam A, Strathman AR, Hou X, Correia C, Meng XW, McGehee CD, Balczewski EA, Duffield LN, Rossman OK, Wong C, Dai H, Hurley RM, Wagner JM, Singh S, Flatten KS, Peterson KL, Schneider PA, De Lorenzo SB, Larson MC, Oberg AL, Wahner Hendrickson AE, Wu X, Pandey A, Li H, Weroha SJ, Kaufmann SH

Open source

DOI: 10.1038/s41392-026-02870-7
Published: 2026 Sep 21
Container: Signal transduction and targeted therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41392-026-02870-7,
  title = {BCLX(L) blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.},
  author = {Venkatachalam A and Strathman AR and Hou X and Correia C and Meng XW and McGehee CD and Balczewski EA and Duffield LN and Rossman OK and Wong C and Dai H and Hurley RM and Wagner JM and Singh S and Flatten KS and Peterson KL and Schneider PA and De Lorenzo SB and Larson MC and Oberg AL and Wahner Hendrickson AE and Wu X and Pandey A and Li H and Weroha SJ and Kaufmann SH},
  year = {2026},
  journal = {Signal transduction and targeted therapy},
  doi = {10.1038/s41392-026-02870-7},
  url = {https://doi.org/10.1038/s41392-026-02870-7}
}

RIS

TY  - JOUR
TI  - BCLX(L) blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.
AU  - Venkatachalam A
AU  - Strathman AR
AU  - Hou X
AU  - Correia C
AU  - Meng XW
AU  - McGehee CD
AU  - Balczewski EA
AU  - Duffield LN
AU  - Rossman OK
AU  - Wong C
AU  - Dai H
AU  - Hurley RM
AU  - Wagner JM
AU  - Singh S
AU  - Flatten KS
AU  - Peterson KL
AU  - Schneider PA
AU  - De Lorenzo SB
AU  - Larson MC
AU  - Oberg AL
AU  - Wahner Hendrickson AE
AU  - Wu X
AU  - Pandey A
AU  - Li H
AU  - Weroha SJ
AU  - Kaufmann SH
PY  - 2026
JO  - Signal transduction and targeted therapy
DO  - 10.1038/s41392-026-02870-7
UR  - https://doi.org/10.1038/s41392-026-02870-7
ER  -

APA

A, V., AR, S., X, H., C, C., XW, M., CD, M., EA, B., LN, D., OK, R., C, W., H, D., RM, H., JM, W., S, S., KS, F., KL, P., PA, S., SB, D. L., MC, L., AL, O., AE, W. H., X, W., A, P., H, L., SJ, W., & SH, K. (2026). BCLX(L) blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-02870-7

Source records

pubmed · retrieved 2026-09-25T10:07:58.328Z